CoChat
Sign Up
Cited by 31

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Ubiquitin-specific protease 8 inhibitor suppresses adrenocorticotropic hormone production and corticotroph tumor cell proliferation

Kageyama, Kazunori, Asari, Yuko, Sugimoto, Yuko, Niioka, Kanako, Daimon, Makoto·2020·Endocrine Journal
DOI 10.1507/endocrj.ej19-0239
Open this paper in CoChat — free account

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1507/endocrj.ej19-0239

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Both inhibitors kill HCT116 colon cancer cells and PC-3 prostate cancer cells, and DUBs-IN-2 has been used to diminish tumorigenesis in breast cancer and in corticotroph tumor cells.

    “Both inhibitors kill HCT116 colon cancer cells and PC-3 prostate cancer cells, and DUBs-IN-2 has been used to diminish tumorigenesis in breast cancer [7] and in corticotroph tumor cells [8].”

    From USP8 Down-Regulation Promotes Parkin-Independent Mitophagy in the Drosophila Brain and in Human Neurons (2023) · cites this paper as [8]

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Flagged first, then by citations

Research works printed but not linked: 28

  1. 1 Kageyama K, Oki Y, Sakihara S, Nigawara T, Terui K, et al. (2013) Evaluation of the diagnostic criteria for Cushing’s disease in Japan. Endocr J 60: 127–135. · DOI
  2. 3 Biller BM, Grossman AB, Stewart PM, Melmed S, Bertagna X, et al. (2008) Treatment of adrenocorticotropin-dependent Cushing’s syndrome; a consensus statement. J Clin Endocrinol Metab 93: 2454–2462. · DOI · Paper page
  3. 4 Bertagna X, Guignat L (2013) Approach to the Cushing’s disease patient with persistent/recurrent hypercortisolism after pituitary surgery. J Clin Endocrinol Metab 98: 1307–1318. · DOI
  4. 5 Rhode PR, Gorski J (1991) Growth and cell cycle regulation of mRNA levels in GH3 cells. Mol Cell Endocrinol 82: 11–22. · DOI
  5. 6 Schteingart DE (2009) Drugs in the medical treatment of Cushing’s syndrome. Expert Opin Emerg Drugs 14: 661–671. · DOI
  6. 7 Reincke M, Sbiera S, Hayakawa A, Theodoropoulou M, Osswald A, et al. (2015) Mutations in the deubiquitinase gene USP8 cause Cushing’s disease. Nat Genet 47: 31–38. · DOI
  7. 8 Ma ZY, Song ZJ, Chen JH, Wang YF, Li SQ, et al. (2015) Recurrent gain-of-function USP8 mutations in Cushing’s disease. Cell Res 25: 306–317. · DOI
  8. 9 Hayashi K, Inoshita N, Kawaguchi K, Ibrahim Ardisasmita A, Suzuki H, et al. (2016) The USP8 mutational status may predict drug susceptibility in corticotroph adenomas of Cushing’s disease. Eur J Endocrinol 174: 213–226. · DOI
  9. 10 Theodoropoulou M, Arzberger T, Gruebler Y, Jaffrain-Rea ML, Schlegel J, et al. (2004) Expression of epidermal growth factor receptor in neoplastic pituitary cells: evidence for a role in corticotropinoma cells. J Endocrinol 183: 385–394. · DOI
  10. 11 Fukuoka H, Cooper O, Ben-Shlomo A, Mamelak A, Ren SG, et al. (2011) EGFR as a therapeutic target for human, canine, and mouse ACTH-secreting pituitary adenomas. J Clin Invest 121: 4712–4721. · DOI
  11. 12 Colombo M, Vallese S, Peretto I, Jacq X, Rain JC, et al. (2010) Synthesis and biological evaluation of 9-oxo-9H-indeno[1,2-b]pyrazine-2,3-dicarbonitrile analogues as potential inhibitors of deubiquitinating enzymes. Chem Med Chem 5: 552–558. · DOI · Paper page
  12. 14 Jeong CH (2015) Inhibition of ubiquitin-specific peptidase 8 suppresses growth of gefitinib-resistant non-small cell lung cancer cells by inducing apoptosis. J Cancer Prev 20: 57–63. · DOI
  13. 15 Kageyama K, Hanada K, Suda T (2009) Differential regulation of urocortins1-3 mRNA in human umbilical vein endothelial cells. Regul Pept 155: 131–138. · DOI
  14. 16 Kageyama K, Hanada K, Suda T (2010) Differential regulation and roles of urocortins in human adrenal H295R cells. Regul Pept 162: 18–25. · DOI
  15. 17 Asari Y, Kageyama K, Nakada Y, Tasso M, Takayasu S, et al. (2017) Inhibitory effects of a selective Jak2 inhibitor on adrenocorticotropic hormone production and proliferation of corticotroph tumor AtT20 cells. Onco Targets Ther 10: 4329–4338. · DOI
  16. 18 Asari Y, Kageyama K, Sugiyama A, Kogawa H, Niioka K, et al. (2019) Lapatinib decreases the ACTH production and proliferation of corticotroph tumor cells. Endocr J 66: 515–522. · DOI
  17. 19 Jian FF, Li YF, Chen YF, Jiang H, Chen X, et al. (2016) Inhibition of ubiquitin-specific peptidase 8 suppresses adrenocorticotropic hormone production and tumorous corticotroph cell growth in AtT20 cells. Chin Med J (Engl) 129: 2102–2108. · DOI
  18. 20 Kageyama K, Sugiyama A, Murasawa S, Asari Y, Niioka K, et al. (2015) Aphidicolin inhibits cell proliferation via the p53-GADD45β pathway in AtT-20 cells. Endocr J 62: 645–654. · DOI
  19. 21 Chesnokova V, Zonis S, Wawrowsky K, Tani Y, Ben-Shlomo A, et al. (2012) Clusterin and FOXL2 act concordantly to regulate pituitary gonadotroph adenoma growth. Mol Endocrinol 26: 2092–2103. · DOI
  20. 22 Pei L, Melmed S (1997) Isolation and characterization of a pituitary tumor-transforming gene (PTTG). Mol Endocrinol 11: 433–441. · DOI
  21. 23 Zhang X, Horwitz GA, Heaney AP, Nakashima M, Prezant TR, et al. (1999) Pituitary tumor transforming gene (PTTG) expression in pituitary adenomas. J Clin Endocrinol Metab 84: 761–767. · DOI
  22. 24 Chesnokova V, Zonis S, Zhou C, Ben-Shlomo A, Wawrowsky K, et al. (2011) Lineage-specific restraint of pituitary gonadotroph cell adenoma growth. PLoS One 6: e17924. · DOI
  23. 25 Nakada Y, Kageyama K, Sugiyama A, Desaki R, Takayasu S, et al. (2015) Inhibitory effects of trichostatin A on adrenocorticotropic hormone production and proliferation of corticotroph tumor AtT-20 cells. Endocr J 62: 1083–1090. · DOI
  24. 27 Michaelis KA, Knox AJ, Xu M, Kiseljak-Vassiliades K, Edwards MG, et al. (2011) Identification of growth arrest and DNA-damage-inducible gene beta (GADD45beta) as a novel tumor suppressor in pituitary gonadotrope tumors. Endocrinology 152: 3603–3613. · DOI
  25. 28 Roussel-Gervais A, Couture C, Langlais D, Takayasu S, Balsalobre A, et al. (2016) The Cables1 gene in glucocorticoid regulation of pituitary corticotrope growth and Cushing disease. J Clin Endocrinol Metab 101: 513–522. · DOI
  26. 29 Hernández-Ramírez LC, Gam R, Valdés N, Lodish MB, Pankratz N, et al. (2017) Loss-of-function mutations in the CABLES1 gene are a novel cause of Cushing’s disease. Endocr Relat Cancer 24: 379–392. · DOI
  27. 30 Riebold M, Kozany C, Freiburger L, Sattler M, Buchfelder M, et al. (2015) A C-terminal HSP90 inhibitor restores glucocorticoid sensitivity and relieves a mouse allograft model of Cushing disease. Nat Med 21: 276–280. · DOI
  28. 31 Sugiyama A, Kageyama K, Murasawa S, Ishigame N, Niioka K, et al. (2015) Inhibition of heat shock protein 90 decreases ACTH production and cell proliferation in AtT-20 cells. Pituitary 18: 542–553. · DOI

Cited by

Sorted by citations

Metadata

Authors
Kageyama, K., Asari, Y., Sugimoto, Y., Niioka, K., & Daimon, M.
Affiliations
Department of Endocrinology and Metabolism, Hirosaki University Graduate School of Medicine, Hirosaki, Aomori 036-8562, Japan
Venue
Endocrine Journal
Publisher
Japan Endocrine Society
Published
2020
Volume
67
Issue
2
Pages
177-184
ISSN
  • 0918-8959
  • 1348-4540
DOI
10.1507/endocrj.ej19-0239
Cited by
31
References
1
Language
en

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review